| Stock Name | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|---|---|---|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 1,012 @ USD 417.21 | USD 422,217 | The ETF bought 1012 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 417.21 compared to the previous average buy price of 414.72. This is 0.6% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 3,517 @ USD 118.5 | USD 416,765 | The ETF bought 3517 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 118.5 compared to the previous average buy price of 112.083. This is 5.7% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 1,381 @ USD 291.77 | USD 402,934 | The ETF bought 1381 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 291.77 compared to the previous average buy price of 286.32. This is 1.9% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 494 @ USD 652.91 | USD 322,538 | The ETF bought 494 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 652.91 compared to the previous average buy price of 624.073. This is 4.6% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 621 @ USD 481.59 | USD 299,067 | The ETF bought 621 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 481.59 compared to the previous average buy price of 368.258. This is 30.8% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 2,489 @ USD 82.23 | USD 204,670 | The ETF bought 2489 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 82.23 compared to the previous average buy price of 73.9727. This is 11.2% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 1,015 @ USD 166.95 | USD 169,454 | The ETF bought 1015 new shares of INSM (Insmed Inc). The shares were bought for an average price of 166.95 compared to the previous average buy price of 114.308. This is 46.1% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 146 @ USD 821.97 | USD 120,008 | The ETF bought 146 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 821.97 compared to the previous average buy price of 619.221. This is 32.7% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 730 @ USD 147.86 | USD 107,938 | The ETF bought 730 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 147.86 compared to the previous average buy price of 136.695. This is 8.2% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 237 @ USD 455.32 | USD 107,911 | The ETF bought 237 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 455.32 compared to the previous average buy price of 332.148. This is 37.1% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 1,041 @ USD 90.18 | USD 93,877 | The ETF bought 1041 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 90.18 compared to the previous average buy price of 72.0279. This is 25.2% higher than average price of previous purchases of INCY. |
| MEDP - Medpace Holdings Inc | BUY | 155 @ USD 584.57 | USD 90,608 | The ETF bought 155 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 584.57 compared to the previous average buy price of 372.613. This is 56.9% higher than average price of previous purchases of MEDP. |
| SNY - Sanofi ADR | BUY | 1,602 @ USD 50.68 | USD 81,189 | The ETF bought 1602 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 50.68 compared to the previous average buy price of 49.9311. This is 1.5% higher than average price of previous purchases of SNY. |
| SMMT - Summit Therapeutics PLC | BUY | 4,343 @ USD 18.66 | USD 81,040 | The ETF bought 4343 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 18.66 compared to the previous average buy price of 21.773. This is -14.3% lower than average price of previous purchases of SMMT. |
| BBIO - BridgeBio Pharma Inc | BUY | 1,210 @ USD 66.62 | USD 80,610 | The ETF bought 1210 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 66.62 compared to the previous average buy price of 42.7234. This is 55.9% higher than average price of previous purchases of BBIO. |
| NBIX - Neurocrine Biosciences Inc | BUY | 575 @ USD 138.02 | USD 79,362 | The ETF bought 575 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 138.02 compared to the previous average buy price of 128.7. This is 7.2% higher than average price of previous purchases of NBIX. |
| VTRS - Viatris Inc | BUY | 7,380 @ USD 10.27 | USD 75,793 | The ETF bought 7380 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.27 compared to the previous average buy price of 9.4967. This is 8.1% higher than average price of previous purchases of VTRS. |
| MRUS - Merus BV | BUY | 792 @ USD 94.81 | USD 75,090 | The ETF bought 792 new shares of MRUS (Merus BV). The shares were bought for an average price of 94.81 compared to the previous average buy price of 60.4674. This is 56.8% higher than average price of previous purchases of MRUS. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 1,031 @ USD 71.88 | USD 74,108 | The ETF bought 1031 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 71.88 compared to the previous average buy price of 45.6892. This is 57.3% higher than average price of previous purchases of IONS. |
| RVMD - Revolution Medicines Inc | BUY | 1,251 @ USD 58.02 | USD 72,583 | The ETF bought 1251 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 58.02 compared to the previous average buy price of 39.7948. This is 45.8% higher than average price of previous purchases of RVMD. |
| GH - Guardant Health Inc | BUY | 930 @ USD 72.27 | USD 67,211 | The ETF bought 930 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 72.27 compared to the previous average buy price of 51.5509. This is 40.2% higher than average price of previous purchases of GH. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 548 @ USD 113.89 | USD 62,412 | The ETF bought 548 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 113.89 compared to the previous average buy price of 72.1211. This is 57.9% higher than average price of previous purchases of RYTM. |
| RPRX - Royalty Pharma Plc | BUY | 1,434 @ USD 36.67 | USD 52,585 | The ETF bought 1434 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 36.67 compared to the previous average buy price of 35.3311. This is 3.8% higher than average price of previous purchases of RPRX. |
| ILMN - Illumina Inc | BUY | 510 @ USD 95.03 | USD 48,465 | The ETF bought 510 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 95.03 compared to the previous average buy price of 96.4409. This is -1.5% lower than average price of previous purchases of ILMN. |
| DYN - Dyne Therapeutics Inc | BUY | 1,981 @ USD 23.63 | USD 46,811 | The ETF bought 1981 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 23.63 compared to the previous average buy price of 11.9337. This is 98.0% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 1,981 @ USD 23.63 | USD 46,811 | The ETF bought 1981 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 23.63 compared to the previous average buy price of 11.9337. This is 98.0% higher than average price of previous purchases of DYN. |
| GRAL - GRAIL, LLC | BUY | 548 @ USD 85.21 | USD 46,695 | The ETF bought 548 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 85.21 compared to the previous average buy price of 48.0316. This is 77.4% higher than average price of previous purchases of GRAL. |
| IDYA - Ideaya Biosciences Inc | BUY | 1,418 @ USD 32.18 | USD 45,631 | The ETF bought 1418 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 32.18 compared to the previous average buy price of 22.1758. This is 45.1% higher than average price of previous purchases of IDYA. |
| VCYT - Veracyte Inc | BUY | 1,275 @ USD 35.41 | USD 45,148 | The ETF bought 1275 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 35.41 compared to the previous average buy price of 30.3567. This is 16.6% higher than average price of previous purchases of VCYT. |
| IRON - Ironveld Plc | BUY | 522 @ USD 85 | USD 44,370 | The ETF bought 522 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 85 compared to the previous average buy price of 56.0274. This is 51.7% higher than average price of previous purchases of IRON. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 4,458 @ USD 9.62 | USD 42,886 | The ETF bought 4458 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 9.62 compared to the previous average buy price of 5.53354. This is 73.8% higher than average price of previous purchases of XERS. |
| ROIV - Roivant Sciences Ltd | BUY | 2,266 @ USD 18.76 | USD 42,510 | The ETF bought 2266 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 18.76 compared to the previous average buy price of 12.2036. This is 53.7% higher than average price of previous purchases of ROIV. |
| ASND - Ascendis Pharma AS | BUY | 202 @ USD 205.71 | USD 41,553 | The ETF bought 202 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 205.71 compared to the previous average buy price of 175.474. This is 17.2% higher than average price of previous purchases of ASND. |
| URGN - UroGen Pharma Ltd | BUY | 1,904 @ USD 19.78 | USD 37,661 | The ETF bought 1904 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 19.78 compared to the previous average buy price of 13.5858. This is 45.6% higher than average price of previous purchases of URGN. |
| PACB - Pacific Biosciences of California | BUY | 18,460 @ USD 2.01 | USD 37,105 | The ETF bought 18460 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.01 compared to the previous average buy price of 1.43552. This is 40.0% higher than average price of previous purchases of PACB. |
| EXEL - Exelixis Inc | BUY | 894 @ USD 39.43 | USD 35,250 | The ETF bought 894 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 39.43 compared to the previous average buy price of 41.0171. This is -3.9% lower than average price of previous purchases of EXEL. |
| BNTX - BioNTech SE | BUY | 334 @ USD 103.35 | USD 34,519 | The ETF bought 334 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 103.35 compared to the previous average buy price of 105.355. This is -1.9% lower than average price of previous purchases of BNTX. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 636 @ USD 51.86 | USD 32,983 | The ETF bought 636 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 51.86 compared to the previous average buy price of 58.7199. This is -11.7% lower than average price of previous purchases of BMRN. |
| MRNA - Moderna Inc | BUY | 1,292 @ USD 24.7 | USD 31,912 | The ETF bought 1292 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 24.7 compared to the previous average buy price of 29.5224. This is -16.3% lower than average price of previous purchases of MRNA. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 74 @ USD 421.6 | USD 31,198 | The ETF bought 74 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 421.6 compared to the previous average buy price of 337.467. This is 24.9% higher than average price of previous purchases of MDGL. |
| RNA - Avidity Biosciences Inc | BUY | 426 @ USD 69.65 | USD 29,671 | The ETF bought 426 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 69.65 compared to the previous average buy price of 34.2211. This is 103.5% higher than average price of previous purchases of RNA. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 202 @ USD 135.73 | USD 27,417 | The ETF bought 202 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 135.73 compared to the previous average buy price of 120.418. This is 12.7% higher than average price of previous purchases of JAZZ. |
| HALO - Halozyme Therapeutics Inc | BUY | 388 @ USD 65.26 | USD 25,321 | The ETF bought 388 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 65.26 compared to the previous average buy price of 58.9409. This is 10.7% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 396 @ USD 61.99 | USD 24,548 | The ETF bought 396 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 61.99 compared to the previous average buy price of 41.0268. This is 51.1% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 222 @ USD 102.97 | USD 22,859 | The ETF bought 222 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 102.97 compared to the previous average buy price of 80.6563. This is 27.7% higher than average price of previous purchases of NUVL. |
| AXSM - Axsome Therapeutics Inc | BUY | 166 @ USD 133.33 | USD 22,133 | The ETF bought 166 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 133.33 compared to the previous average buy price of 112.703. This is 18.3% higher than average price of previous purchases of AXSM. |
| CRSP - Crispr Therapeutics AG | BUY | 302 @ USD 62.56 | USD 18,893 | The ETF bought 302 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 62.56 compared to the previous average buy price of 52.0215. This is 20.3% higher than average price of previous purchases of CRSP. |
| PCVX - Vaxcyte Inc | BUY | 432 @ USD 43.52 | USD 18,801 | The ETF bought 432 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 43.52 compared to the previous average buy price of 44.4138. This is -2.0% lower than average price of previous purchases of PCVX. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 460 @ USD 40.29 | USD 18,533 | The ETF bought 460 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 40.29 compared to the previous average buy price of 19.757. This is 103.9% higher than average price of previous purchases of ARWR. |
| PTCT - PTC Therapeutics Inc | BUY | 264 @ USD 67.35 | USD 17,780 | The ETF bought 264 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 67.35 compared to the previous average buy price of 53.4951. This is 25.9% higher than average price of previous purchases of PTCT. |
| KRYS - Krystal Biotech Inc | BUY | 96 @ USD 185.05 | USD 17,765 | The ETF bought 96 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 185.05 compared to the previous average buy price of 157.628. This is 17.4% higher than average price of previous purchases of KRYS. |
| ALKS - Alkermes Plc | BUY | 550 @ USD 31.45 | USD 17,298 | The ETF bought 550 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 31.45 compared to the previous average buy price of 30.361. This is 3.6% higher than average price of previous purchases of ALKS. |
| PTGX - Protagonist Therapeutics Inc | BUY | 208 @ USD 76.69 | USD 15,952 | The ETF bought 208 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 76.69 compared to the previous average buy price of 54.6503. This is 40.3% higher than average price of previous purchases of PTGX. |
| ACLX - Arcellx Inc | BUY | 184 @ USD 86.03 | USD 15,830 | The ETF bought 184 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 86.03 compared to the previous average buy price of 70.728. This is 21.6% higher than average price of previous purchases of ACLX. |
| AKRO - Akero Therapeutics Inc | BUY | 266 @ USD 54 | USD 14,364 | The ETF bought 266 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54 compared to the previous average buy price of 48.9087. This is 10.4% higher than average price of previous purchases of AKRO. |
| KYMR - Kymera Therapeutics Inc | BUY | 238 @ USD 60.03 | USD 14,287 | The ETF bought 238 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 60.03 compared to the previous average buy price of 45.3108. This is 32.5% higher than average price of previous purchases of KYMR. |
| PRAX - Praxis Precision Medicines Inc | BUY | 70 @ USD 195.76 | USD 13,703 | The ETF bought 70 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 195.76 compared to the previous average buy price of 52.8338. This is 270.5% higher than average price of previous purchases of PRAX. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 314 @ USD 42.9 | USD 13,471 | The ETF bought 314 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 42.9 compared to the previous average buy price of 34.247. This is 25.3% higher than average price of previous purchases of CRNX. |
| QURE - Uniqure NV | BUY | 182 @ USD 70.59 | USD 12,847 | The ETF bought 182 new shares of QURE (Uniqure NV). The shares were bought for an average price of 70.59 compared to the previous average buy price of 20.9909. This is 236.3% higher than average price of previous purchases of QURE. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 566 @ USD 22.53 | USD 12,752 | The ETF bought 566 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 22.53 compared to the previous average buy price of 20.6909. This is 8.9% higher than average price of previous purchases of ACAD. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 424 @ USD 30.05 | USD 12,741 | The ETF bought 424 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 30.05 compared to the previous average buy price of 20.8957. This is 43.8% higher than average price of previous purchases of APLS. |
| IMVT - Immunovant Inc | BUY | 586 @ USD 21.65 | USD 12,687 | The ETF bought 586 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 21.65 compared to the previous average buy price of 17.6031. This is 23.0% higher than average price of previous purchases of IMVT. |
| ADMA - ADMA Biologics Inc | BUY | 800 @ USD 15.53 | USD 12,424 | The ETF bought 800 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 15.53 compared to the previous average buy price of 17.5737. This is -11.6% lower than average price of previous purchases of ADMA. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 66 @ USD 184.52 | USD 12,178 | The ETF bought 66 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 184.52 compared to the previous average buy price of 127.763. This is 44.4% higher than average price of previous purchases of LGND. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 168 @ USD 70.46 | USD 11,837 | The ETF bought 168 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 70.46 compared to the previous average buy price of 54.1398. This is 30.1% higher than average price of previous purchases of MIRM. |
| RARE - Ultragenyx | BUY | 324 @ USD 34.59 | USD 11,207 | The ETF bought 324 new shares of RARE (Ultragenyx). The shares were bought for an average price of 34.59 compared to the previous average buy price of 36.4917. This is -5.2% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 324 @ USD 34.59 | USD 11,207 | The ETF bought 324 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 34.59 compared to the previous average buy price of 36.4917. This is -5.2% lower than average price of previous purchases of RARE. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,056 @ USD 10.43 | USD 11,014 | The ETF bought 1056 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 10.43 compared to the previous average buy price of 8.6397. This is 20.7% higher than average price of previous purchases of AMRX. |
| CGON - CG Oncology, Inc. Common stock | BUY | 256 @ USD 42.98 | USD 11,003 | The ETF bought 256 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 42.98 compared to the previous average buy price of 29.0466. This is 48.0% higher than average price of previous purchases of CGON. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 258 @ USD 42.3 | USD 10,913 | The ETF bought 258 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.3 compared to the previous average buy price of 35.026. This is 20.8% higher than average price of previous purchases of XENE. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 188 @ USD 55.68 | USD 10,468 | The ETF bought 188 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 55.68 compared to the previous average buy price of 36.1117. This is 54.2% higher than average price of previous purchases of SUPN. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 396 @ USD 25.29 | USD 10,015 | The ETF bought 396 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 25.29 compared to the previous average buy price of 15.4682. This is 63.5% higher than average price of previous purchases of ARQT. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 142 @ USD 67.52 | USD 9,588 | The ETF bought 142 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 67.52 compared to the previous average buy price of 47.3732. This is 42.5% higher than average price of previous purchases of TARS. |
| SRRK - Scholar Rock Holding Corp | BUY | 322 @ USD 29.27 | USD 9,425 | The ETF bought 322 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 29.27 compared to the previous average buy price of 35.355. This is -17.2% lower than average price of previous purchases of SRRK. |
| FOLD - Amicus Therapeutics Inc | BUY | 1,018 @ USD 8.9 | USD 9,060 | The ETF bought 1018 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 8.9 compared to the previous average buy price of 7.2077. This is 23.5% higher than average price of previous purchases of FOLD. |
| LEGN - Legend Biotech Corp | BUY | 280 @ USD 32.13 | USD 8,996 | The ETF bought 280 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 32.13 compared to the previous average buy price of 35.0557. This is -8.3% lower than average price of previous purchases of LEGN. |
| TVTX - Travere Therapeutics Inc | BUY | 294 @ USD 29.98 | USD 8,814 | The ETF bought 294 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 29.98 compared to the previous average buy price of 18.7616. This is 59.8% higher than average price of previous purchases of TVTX. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 218 @ USD 40.14 | USD 8,751 | The ETF bought 218 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 40.14 compared to the previous average buy price of 18.358. This is 118.7% higher than average price of previous purchases of MLYS. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 152 @ USD 55.7 | USD 8,466 | The ETF bought 152 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 55.7 compared to the previous average buy price of 42.5371. This is 30.9% higher than average price of previous purchases of APGE. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,438 @ USD 5.87 | USD 8,441 | The ETF bought 1438 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 5.87 compared to the previous average buy price of 5.81778. This is 0.9% higher than average price of previous purchases of RXRX. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 502 @ USD 16.8 | USD 8,434 | The ETF bought 502 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 16.8 compared to the previous average buy price of 11.4973. This is 46.1% higher than average price of previous purchases of ADPT. |
| BEAM - Beam Therapeutics Inc | BUY | 334 @ USD 24.77 | USD 8,273 | The ETF bought 334 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 24.77 compared to the previous average buy price of 20.4178. This is 21.3% higher than average price of previous purchases of BEAM. |
| AGIO - Agios Pharm | BUY | 192 @ USD 41.96 | USD 8,056 | The ETF bought 192 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 41.96 compared to the previous average buy price of 35.4463. This is 18.4% higher than average price of previous purchases of AGIO. |
| DNLI - Denali Therapeutics Inc | BUY | 482 @ USD 16.25 | USD 7,833 | The ETF bought 482 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 16.25 compared to the previous average buy price of 15.0262. This is 8.1% higher than average price of previous purchases of DNLI. |
| IBRX - Immunitybio Inc | BUY | 3,172 @ USD 2.42 | USD 7,676 | The ETF bought 3172 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.42 compared to the previous average buy price of 2.79007. This is -13.3% lower than average price of previous purchases of IBRX. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 316 @ USD 23.98 | USD 7,578 | The ETF bought 316 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 23.98 compared to the previous average buy price of 15.9804. This is 50.1% higher than average price of previous purchases of CNTA. |
| SRPT - Sarepta Therapeutics Inc | BUY | 322 @ USD 23.45 | USD 7,551 | The ETF bought 322 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 23.45 compared to the previous average buy price of 35.0495. This is -33.1% lower than average price of previous purchases of SRPT. |
| COGT - Cogent Biosciences Inc | BUY | 462 @ USD 16 | USD 7,392 | The ETF bought 462 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 16 compared to the previous average buy price of 10.3869. This is 54.0% higher than average price of previous purchases of COGT. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 72 @ USD 92.23 | USD 6,641 | The ETF bought 72 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 92.23 compared to the previous average buy price of 70.3088. This is 31.2% higher than average price of previous purchases of ANIP. |
| OCUL - Ocular Therapeutix Inc | BUY | 576 @ USD 11.48 | USD 6,612 | The ETF bought 576 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.48 compared to the previous average buy price of 9.8545. This is 16.5% higher than average price of previous purchases of OCUL. |
| TWST - Twist Bioscience Corp | BUY | 200 @ USD 32.21 | USD 6,442 | The ETF bought 200 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 32.21 compared to the previous average buy price of 36.7237. This is -12.3% lower than average price of previous purchases of TWST. |
| VERA - Vera Therapeutics Inc | BUY | 210 @ USD 29.36 | USD 6,166 | The ETF bought 210 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 29.36 compared to the previous average buy price of 26.6433. This is 10.2% higher than average price of previous purchases of VERA. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 322 @ USD 18.9 | USD 6,086 | The ETF bought 322 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 18.9 compared to the previous average buy price of 10.2666. This is 84.1% higher than average price of previous purchases of AVDL. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 196 @ USD 29.57 | USD 5,796 | The ETF bought 196 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 29.57 compared to the previous average buy price of 22.153. This is 33.5% higher than average price of previous purchases of GPCR. |
| VCEL - Vericel Corp Ord | BUY | 166 @ USD 34.88 | USD 5,790 | The ETF bought 166 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 34.88 compared to the previous average buy price of 41.0937. This is -15.1% lower than average price of previous purchases of VCEL. |
| STOK - Stoke Therapeutics Inc | BUY | 184 @ USD 31.41 | USD 5,779 | The ETF bought 184 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 31.41 compared to the previous average buy price of 14.5971. This is 115.2% higher than average price of previous purchases of STOK. |
| EWTX - Edgewise Therapeutics Inc | BUY | 348 @ USD 16.33 | USD 5,683 | The ETF bought 348 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 16.33 compared to the previous average buy price of 15.6397. This is 4.4% higher than average price of previous purchases of EWTX. |
| MNKD - MannKind Corp | BUY | 1,018 @ USD 5.54 | USD 5,640 | The ETF bought 1018 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.54 compared to the previous average buy price of 4.66795. This is 18.7% higher than average price of previous purchases of MNKD. |
| ABCL - Abcellera Biologics Inc | BUY | 992 @ USD 5.62 | USD 5,575 | The ETF bought 992 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 5.62 compared to the previous average buy price of 3.84744. This is 46.1% higher than average price of previous purchases of ABCL. |
| HRMY - Harmony Biosciences Holdings | BUY | 190 @ USD 29.32 | USD 5,571 | The ETF bought 190 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 29.32 compared to the previous average buy price of 31.9715. This is -8.3% lower than average price of previous purchases of HRMY. |
| JANX - Janux Therapeutics Inc | BUY | 198 @ USD 27.81 | USD 5,506 | The ETF bought 198 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 27.81 compared to the previous average buy price of 27.6386. This is 0.6% higher than average price of previous purchases of JANX. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 146 @ USD 37.38 | USD 5,457 | The ETF bought 146 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 37.38 compared to the previous average buy price of 28.9807. This is 29.0% higher than average price of previous purchases of KNSA. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 436 @ USD 12.22 | USD 5,328 | The ETF bought 436 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 12.22 compared to the previous average buy price of 8.72576. This is 40.0% higher than average price of previous purchases of AUPH. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 696 @ USD 7.31 | USD 5,088 | The ETF bought 696 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.31 compared to the previous average buy price of 8.39193. This is -12.9% lower than average price of previous purchases of BCRX. |
| NVCR - Novocure Ltd | BUY | 370 @ USD 13.48 | USD 4,988 | The ETF bought 370 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.48 compared to the previous average buy price of 17.0476. This is -20.9% lower than average price of previous purchases of NVCR. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 256 @ USD 19.38 | USD 4,961 | The ETF bought 256 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 19.38 compared to the previous average buy price of 13.9048. This is 39.4% higher than average price of previous purchases of ZYME. |
| TXG - 10X Genomics Inc | BUY | 384 @ USD 12.9 | USD 4,954 | The ETF bought 384 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 12.9 compared to the previous average buy price of 11.9947. This is 7.5% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 384 @ USD 12.9 | USD 4,954 | The ETF bought 384 new shares of TXG (Terex Corporation). The shares were bought for an average price of 12.9 compared to the previous average buy price of 11.9947. This is 7.5% higher than average price of previous purchases of TXG. |
| NTLA - Intellia Therapeutics Inc | BUY | 360 @ USD 13.12 | USD 4,723 | The ETF bought 360 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 13.12 compared to the previous average buy price of 12.5382. This is 4.6% higher than average price of previous purchases of NTLA. |
| SYRE - Spyre Therapeutics Inc. | BUY | 198 @ USD 23.83 | USD 4,718 | The ETF bought 198 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 23.83 compared to the previous average buy price of 17.0053. This is 40.1% higher than average price of previous purchases of SYRE. |
| SANA - Sana Biotechnology Inc | BUY | 872 @ USD 5.37 | USD 4,683 | The ETF bought 872 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 5.37 compared to the previous average buy price of 3.1267. This is 71.7% higher than average price of previous purchases of SANA. |
| TSHA - Taysha Gene Therapies Inc | BUY | 906 @ USD 5.01 | USD 4,539 | The ETF bought 906 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 5.01 compared to the previous average buy price of 2.76231. This is 81.4% higher than average price of previous purchases of TSHA. |
| NVAX - Novavax Inc | BUY | 540 @ USD 8.38 | USD 4,525 | The ETF bought 540 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 8.38 compared to the previous average buy price of 7.33253. This is 14.3% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 540 @ USD 8.38 | USD 4,525 | The ETF bought 540 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 8.38 compared to the previous average buy price of 7.33253. This is 14.3% higher than average price of previous purchases of NVAX. |
| HROW - Harrow Health Inc | BUY | 122 @ USD 36.775 | USD 4,487 | The ETF bought 122 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 36.775 compared to the previous average buy price of 33.0252. This is 11.4% higher than average price of previous purchases of HROW. |
| WVE - Wave Life Sciences Ltd | BUY | 542 @ USD 8.26 | USD 4,477 | The ETF bought 542 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 8.26 compared to the previous average buy price of 8.47065. This is -2.5% lower than average price of previous purchases of WVE. |
| IMCR - Immunocore Holdings Ltd | BUY | 136 @ USD 32.85 | USD 4,468 | The ETF bought 136 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 32.85 compared to the previous average buy price of 32.6717. This is 0.5% higher than average price of previous purchases of IMCR. |
| ELVN - Enliven Therapeutics Inc. | BUY | 196 @ USD 22.65 | USD 4,439 | The ETF bought 196 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 22.65 compared to the previous average buy price of 20.2579. This is 11.8% higher than average price of previous purchases of ELVN. |
| RLAY - Relay Therapeutics Inc | BUY | 574 @ USD 7.31 | USD 4,196 | The ETF bought 574 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.31 compared to the previous average buy price of 3.97474. This is 83.9% higher than average price of previous purchases of RLAY. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 322 @ USD 12.93 | USD 4,163 | The ETF bought 322 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 12.93 compared to the previous average buy price of 10.3511. This is 24.9% higher than average price of previous purchases of ORIC. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 296 @ USD 13.89 | USD 4,111 | The ETF bought 296 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 13.89 compared to the previous average buy price of 6.54141. This is 112.3% higher than average price of previous purchases of AMLX. |
| PGEN - Precigen Inc | BUY | 1,014 @ USD 4.01 | USD 4,066 | The ETF bought 1014 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.01 compared to the previous average buy price of 2.11628. This is 89.5% higher than average price of previous purchases of PGEN. |
| CVAC - CureVac NV | BUY | 748 @ USD 5.38 | USD 4,024 | The ETF bought 748 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.38 compared to the previous average buy price of 4.80308. This is 12.0% higher than average price of previous purchases of CVAC. |
| DVAX - Dynavax Technologies Corporation | BUY | 390 @ USD 10.3 | USD 4,017 | The ETF bought 390 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.3 compared to the previous average buy price of 10.4692. This is -1.6% lower than average price of previous purchases of DVAX. |
| ZLAB - Zai Lab Ltd | BUY | 158 @ USD 25.32 | USD 4,001 | The ETF bought 158 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 25.32 compared to the previous average buy price of 34.5833. This is -26.8% lower than average price of previous purchases of ZLAB. |
| GMAB - Genmab AS | BUY | 138 @ USD 28.95 | USD 3,995 | The ETF bought 138 new shares of GMAB (Genmab AS). The shares were bought for an average price of 28.95 compared to the previous average buy price of 22.9399. This is 26.2% higher than average price of previous purchases of GMAB. |
| ARDX - Ardelyx Inc | BUY | 802 @ USD 4.96 | USD 3,978 | The ETF bought 802 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 4.96 compared to the previous average buy price of 4.56423. This is 8.7% higher than average price of previous purchases of ARDX. |
| GRFS - Grifols SA ADR | BUY | 406 @ USD 9.39 | USD 3,812 | The ETF bought 406 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.39 compared to the previous average buy price of 9.48465. This is -1.0% lower than average price of previous purchases of GRFS. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 286 @ USD 13.22 | USD 3,781 | The ETF bought 286 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 13.22 compared to the previous average buy price of 11.4023. This is 15.9% higher than average price of previous purchases of SNDX. |
| AMPH - Amphastar P | BUY | 154 @ USD 24.24 | USD 3,733 | The ETF bought 154 new shares of AMPH (Amphastar P). The shares were bought for an average price of 24.24 compared to the previous average buy price of 25.4885. This is -4.9% lower than average price of previous purchases of AMPH. |
| INVA - Innoviva Inc | BUY | 208 @ USD 17.57 | USD 3,655 | The ETF bought 208 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 17.57 compared to the previous average buy price of 18.8831. This is -7.0% lower than average price of previous purchases of INVA. |
| COLL - Collegium Pharmaceutical Inc | BUY | 104 @ USD 34.81 | USD 3,620 | The ETF bought 104 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 34.81 compared to the previous average buy price of 31.1052. This is 11.9% higher than average price of previous purchases of COLL. |
| XNCR - Xencor Inc | BUY | 238 @ USD 14.67 | USD 3,491 | The ETF bought 238 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 14.67 compared to the previous average buy price of 10.8928. This is 34.7% higher than average price of previous purchases of XNCR. |
| MNMD - Mind Medicine Inc | BUY | 258 @ USD 12.91 | USD 3,331 | The ETF bought 258 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.91 compared to the previous average buy price of 8.23808. This is 56.7% higher than average price of previous purchases of MNMD. |
| ANAB - AnaptysBio Inc | BUY | 92 @ USD 36.12 | USD 3,323 | The ETF bought 92 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 36.12 compared to the previous average buy price of 23.1718. This is 55.9% higher than average price of previous purchases of ANAB. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 240 @ USD 13.53 | USD 3,247 | The ETF bought 240 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 13.53 compared to the previous average buy price of 8.57568. This is 57.8% higher than average price of previous purchases of PHAT. |
| FTRE - Fortrea Holdings Inc. | BUY | 302 @ USD 10.44 | USD 3,153 | The ETF bought 302 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 10.44 compared to the previous average buy price of 6.27917. This is 66.3% higher than average price of previous purchases of FTRE. |
| NRIX - Nurix Therapeutics Inc | BUY | 268 @ USD 11.7 | USD 3,136 | The ETF bought 268 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 11.7 compared to the previous average buy price of 12.0297. This is -2.7% lower than average price of previous purchases of NRIX. |
| PCRX - Pacira BioSciences, Inc. | BUY | 148 @ USD 21.01 | USD 3,109 | The ETF bought 148 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 21.01 compared to the previous average buy price of 23.9279. This is -12.2% lower than average price of previous purchases of PCRX. |
| KURA - Kura Oncology Inc | BUY | 302 @ USD 10.26 | USD 3,099 | The ETF bought 302 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.26 compared to the previous average buy price of 7.00046. This is 46.6% higher than average price of previous purchases of KURA. |
| ABUS - Arbutus Biopharma Corp | BUY | 652 @ USD 4.61 | USD 3,006 | The ETF bought 652 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.61 compared to the previous average buy price of 3.53676. This is 30.3% higher than average price of previous purchases of ABUS. |
| SPRY - Silverback Therapeutics Inc | BUY | 326 @ USD 8.97999 | USD 2,927 | The ETF bought 326 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 8.97999 compared to the previous average buy price of 14.1853. This is -36.7% lower than average price of previous purchases of SPRY. |
| TNGX - Tango Therapeutics Inc | BUY | 370 @ USD 7.83 | USD 2,897 | The ETF bought 370 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 7.83 compared to the previous average buy price of 5.97653. This is 31.0% higher than average price of previous purchases of TNGX. |
| VIR - Vir Biotechnology Inc | BUY | 460 @ USD 5.91 | USD 2,719 | The ETF bought 460 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.91 compared to the previous average buy price of 5.84114. This is 1.2% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 460 @ USD 5.91 | USD 2,719 | The ETF bought 460 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.91 compared to the previous average buy price of 5.84114. This is 1.2% higher than average price of previous purchases of VIR. |
| PAHC - Phibro Animal Health Corporation | BUY | 66 @ USD 41.19 | USD 2,719 | The ETF bought 66 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 41.19 compared to the previous average buy price of 27.6775. This is 48.8% higher than average price of previous purchases of PAHC. |
| REPL - Replimune Group Inc | BUY | 266 @ USD 10.21 | USD 2,716 | The ETF bought 266 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 10.21 compared to the previous average buy price of 8.79877. This is 16.0% higher than average price of previous purchases of REPL. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 230 @ USD 11.73 | USD 2,698 | The ETF bought 230 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 11.73 compared to the previous average buy price of 8.53875. This is 37.4% higher than average price of previous purchases of EYPT. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 584 @ USD 4.54 | USD 2,651 | The ETF bought 584 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.54 compared to the previous average buy price of 4.57159. This is -0.7% lower than average price of previous purchases of PRME. |
| GERN - Geron Corporation | BUY | 2,112 @ USD 1.23 | USD 2,598 | The ETF bought 2112 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.23 compared to the previous average buy price of 1.53182. This is -19.7% lower than average price of previous purchases of GERN. |
| SVRA - Savara Inc | BUY | 576 @ USD 4.34 | USD 2,500 | The ETF bought 576 new shares of SVRA (Savara Inc). The shares were bought for an average price of 4.34 compared to the previous average buy price of 2.64834. This is 63.9% higher than average price of previous purchases of SVRA. |
| ERAS - Erasca Inc | BUY | 1,016 @ USD 2.36 | USD 2,398 | The ETF bought 1016 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 2.36 compared to the previous average buy price of 1.58596. This is 48.8% higher than average price of previous purchases of ERAS. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 340 @ USD 7.03999 | USD 2,394 | The ETF bought 340 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 7.03999 compared to the previous average buy price of 7.38635. This is -4.7% lower than average price of previous purchases of DAWN. |
| MGTX - MeiraGTx Holdings PLC | BUY | 268 @ USD 8.92999 | USD 2,393 | The ETF bought 268 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.92999 compared to the previous average buy price of 7.12268. This is 25.4% higher than average price of previous purchases of MGTX. |
| TBPH - Theravance Biopharma Inc | BUY | 168 @ USD 14.17 | USD 2,381 | The ETF bought 168 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 14.17 compared to the previous average buy price of 11.4663. This is 23.6% higher than average price of previous purchases of TBPH. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,188 @ USD 2 | USD 2,376 | The ETF bought 1188 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2 compared to the previous average buy price of 2.46191. This is -18.8% lower than average price of previous purchases of IOVA. |
| TERN - Tern Plc | BUY | 292 @ USD 8.02 | USD 2,342 | The ETF bought 292 new shares of TERN (Tern Plc). The shares were bought for an average price of 8.02 compared to the previous average buy price of 5.02316. This is 59.7% higher than average price of previous purchases of TERN. |
| AVXL - Anavex Life Sciences Corp | BUY | 288 @ USD 8.02 | USD 2,310 | The ETF bought 288 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 8.02 compared to the previous average buy price of 9.70831. This is -17.4% lower than average price of previous purchases of AVXL. |
| ARVN - Arvinas Inc | BUY | 240 @ USD 9.59 | USD 2,302 | The ETF bought 240 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 9.59 compared to the previous average buy price of 8.6459. This is 10.9% higher than average price of previous purchases of ARVN. |
| CSTL - Castle Biosciences Inc | BUY | 96 @ USD 23.74 | USD 2,279 | The ETF bought 96 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 23.74 compared to the previous average buy price of 21.0102. This is 13.0% higher than average price of previous purchases of CSTL. |
| RGNX - Regenxbio Inc | BUY | 176 @ USD 12.84 | USD 2,260 | The ETF bought 176 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 12.84 compared to the previous average buy price of 8.90988. This is 44.1% higher than average price of previous purchases of RGNX. |
| KROS - Keros Therapeutics Inc | BUY | 134 @ USD 15.04 | USD 2,015 | The ETF bought 134 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 15.04 compared to the previous average buy price of 13.5731. This is 10.8% higher than average price of previous purchases of KROS. |
| PRTA - Prothena Corporation plc | BUY | 184 @ USD 10.65 | USD 1,960 | The ETF bought 184 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.65 compared to the previous average buy price of 8.85101. This is 20.3% higher than average price of previous purchases of PRTA. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 226 @ USD 8.64 | USD 1,953 | The ETF bought 226 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 8.64 compared to the previous average buy price of 5.33069. This is 62.1% higher than average price of previous purchases of OLMA. |
| SIGA - SIGA Technologies Inc | BUY | 236 @ USD 8.13001 | USD 1,919 | The ETF bought 236 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 8.13001 compared to the previous average buy price of 6.74333. This is 20.6% higher than average price of previous purchases of SIGA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 168 @ USD 11.41 | USD 1,917 | The ETF bought 168 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 11.41 compared to the previous average buy price of 5.70313. This is 100.1% higher than average price of previous purchases of FDMT. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 164 @ USD 10.96 | USD 1,797 | The ETF bought 164 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 10.96 compared to the previous average buy price of 12.4289. This is -11.8% lower than average price of previous purchases of KALV. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 1,274 @ USD 1.33 | USD 1,694 | The ETF bought 1274 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.33 compared to the previous average buy price of 1.01277. This is 31.3% higher than average price of previous purchases of LXRX. |
| EOLS - Evolus Inc | BUY | 236 @ USD 6.85999 | USD 1,619 | The ETF bought 236 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.85999 compared to the previous average buy price of 9.3844. This is -26.9% lower than average price of previous purchases of EOLS. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 526 @ USD 3.07 | USD 1,615 | The ETF bought 526 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.07 compared to the previous average buy price of 2.66854. This is 15.0% higher than average price of previous purchases of MRVI. |
| CGEM - Cullinan Oncology LLC | BUY | 206 @ USD 7.69 | USD 1,584 | The ETF bought 206 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 7.69 compared to the previous average buy price of 7.88179. This is -2.4% lower than average price of previous purchases of CGEM. |
| HCM - HUTCHMED China Ltd | BUY | 106 @ USD 14.71 | USD 1,559 | The ETF bought 106 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.71 compared to the previous average buy price of 15.5604. This is -5.5% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 106 @ USD 14.71 | USD 1,559 | The ETF bought 106 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.71 compared to the previous average buy price of 15.5604. This is -5.5% lower than average price of previous purchases of HCM. |
| GLPG - Galapagos NV ADR | BUY | 50 @ USD 30.92 | USD 1,546 | The ETF bought 50 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 30.92 compared to the previous average buy price of 28.9899. This is 6.7% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 50 @ USD 30.92 | USD 1,546 | The ETF bought 50 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 30.92 compared to the previous average buy price of 28.9899. This is 6.7% higher than average price of previous purchases of GLPG. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 362 @ USD 3.78 | USD 1,368 | The ETF bought 362 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.78 compared to the previous average buy price of 5.23728. This is -27.8% lower than average price of previous purchases of RCKT. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 160 @ USD 8.18001 | USD 1,309 | The ETF bought 160 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 8.18001 compared to the previous average buy price of 8.61703. This is -5.1% lower than average price of previous purchases of BCYC. |
| ACIU - AC Immune Ltd | BUY | 340 @ USD 3.83999 | USD 1,306 | The ETF bought 340 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.83999 compared to the previous average buy price of 2.28037. This is 68.4% higher than average price of previous purchases of ACIU. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 218 @ USD 5.41001 | USD 1,179 | The ETF bought 218 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 5.41001 compared to the previous average buy price of 4.87663. This is 10.9% higher than average price of previous purchases of VNDA. |
| ALT - Altitude Group Plc | BUY | 290 @ USD 4 | USD 1,160 | The ETF bought 290 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4 compared to the previous average buy price of 5.26386. This is -24.0% lower than average price of previous purchases of ALT. |
| AUTL - Autolus Therapeutics Ltd | BUY | 742 @ USD 1.46 | USD 1,083 | The ETF bought 742 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.46 compared to the previous average buy price of 1.88483. This is -22.5% lower than average price of previous purchases of AUTL. |
| LYEL - Lyell Immunopharma Inc | BUY | 64 @ USD 16.59 | USD 1,062 | The ETF bought 64 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 16.59 compared to the previous average buy price of 6.08089. This is 172.8% higher than average price of previous purchases of LYEL. |
| EDIT - Editas Medicine Inc | BUY | 328 @ USD 3.04 | USD 997 | The ETF bought 328 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 3.04 compared to the previous average buy price of 2.72705. This is 11.5% higher than average price of previous purchases of EDIT. |
| TRDA - Entrada Therapeutics Inc | BUY | 140 @ USD 6.89002 | USD 965 | The ETF bought 140 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 6.89002 compared to the previous average buy price of 7.6695. This is -10.2% lower than average price of previous purchases of TRDA. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 288 @ USD 3.29 | USD 948 | The ETF bought 288 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.29 compared to the previous average buy price of 3.35004. This is -1.8% lower than average price of previous purchases of AVIR. |
| HUMA - Humacyte Inc | BUY | 560 @ USD 1.69 | USD 946 | The ETF bought 560 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.69 compared to the previous average buy price of 2.26533. This is -25.4% lower than average price of previous purchases of HUMA. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 98 @ USD 9.43998 | USD 925 | The ETF bought 98 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 9.43998 compared to the previous average buy price of 15.049. This is -37.3% lower than average price of previous purchases of ARCT. |
| ALLO - Allogene Therapeutics Inc | BUY | 754 @ USD 1.22 | USD 920 | The ETF bought 754 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.22 compared to the previous average buy price of 1.34414. This is -9.2% lower than average price of previous purchases of ALLO. |
| VYGR - Voyager Therapeutics Inc | BUY | 178 @ USD 4.60999 | USD 821 | The ETF bought 178 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.60999 compared to the previous average buy price of 3.78618. This is 21.8% higher than average price of previous purchases of VYGR. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 528 @ USD 1.51 | USD 797 | The ETF bought 528 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 1.51 compared to the previous average buy price of 1.08053. This is 39.7% higher than average price of previous purchases of IRWD. |
| OABI - OmniAb Inc. | BUY | 426 @ USD 1.47001 | USD 626 | The ETF bought 426 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.47001 compared to the previous average buy price of 1.96012. This is -25.0% lower than average price of previous purchases of OABI. |
| ALEC - Alector Inc | BUY | 366 @ USD 1.55 | USD 567 | The ETF bought 366 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.55 compared to the previous average buy price of 1.97859. This is -21.7% lower than average price of previous purchases of ALEC. |
| MXCT - MaxCyte Inc | BUY | 368 @ USD 1.50999 | USD 556 | The ETF bought 368 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.50999 compared to the previous average buy price of 2.24832. This is -32.8% lower than average price of previous purchases of MXCT. |
| FATE - Fate Therapeutics Inc | BUY | 374 @ USD 1.34 | USD 501 | The ETF bought 374 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.18528. This is 13.1% higher than average price of previous purchases of FATE. |
| MGNX - MacroGenics Inc | BUY | 214 @ USD 1.68999 | USD 362 | The ETF bought 214 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.68999 compared to the previous average buy price of 1.57969. This is 7.0% higher than average price of previous purchases of MGNX. |
| PLRX - Pliant Therapeutics Inc | BUY | 200 @ USD 1.73999 | USD 348 | The ETF bought 200 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.73999 compared to the previous average buy price of 1.47875. This is 17.7% higher than average price of previous purchases of PLRX. |
| BMEA - Biomea Fusion Inc | BUY | 238 @ USD 1.37001 | USD 326 | The ETF bought 238 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.37001 compared to the previous average buy price of 1.88197. This is -27.2% lower than average price of previous purchases of BMEA. |
| STRO - Sutro Biopharma | BUY | 272 @ USD 1.05 | USD 286 | The ETF bought 272 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 1.05 compared to the previous average buy price of 0.885929. This is 18.5% higher than average price of previous purchases of STRO. |
| MRSN - Mersana Therapeutics Inc | BUY | 16 @ USD 9.55997 | USD 153 | The ETF bought 16 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 9.55997 compared to the previous average buy price of 0.491524. This is 1,845.0% higher than average price of previous purchases of MRSN. |
| OKUR - OKUR | BUY | 42 @ USD 3.18995 | USD 134 | The ETF bought 42 new shares of OKUR (OKUR). The shares were bought for an average price of 3.18995 compared to the previous average buy price of 6.20537. This is -48.6% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. Warning: Undefined variable $fallen in /var/www/liquidata/show_ETF_trades.php on line 177 however if the holding was sold on 2025-10-29 this would crystalise an overall loss. |
Value of shares added and average price calculated using the adjusted close on the day which may not be the price the ETF paid for the shares or sold the share at